Thyrocare Technologies: SEBI Takeover Regulation 31 Disclosure Filed
The disclosure was formally submitted to NSE on 18 August 2026 under SEBI's takeover regime. Regulation 31 of SEBI (SAST) Regulations, 2011 mandates disclosure by the target company within two days of acquisition of shares triggering the threshold. No public details on bidder, offer price, shareholding, or transaction consideration are accessible at this stage.
Why it mattersRegulation 31 filing signals crossing of 25% threshold or formal open-offer commencement; transaction architecture and structuring details are gated pending full offer document publication and SEBI review.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Archives · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026